Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
ORIGINAL ARTICLE

Relationship between kalemia and intensive care unit admission or death in hospitalized COVID-19 patients: A cohort study

A.F. Guédon a,*, A. Delarue a, N. Mohamedi a, A. Roffé a, L. Khider a,b, N. Gendron c, G. Goudot a,b, G. Détriché a,b, R. Chocron b,e, S. Oudard f, D.M. Smadja c,d, T. Mirault a,b, E. Messas a,b

a Vascular medicine department, hôpital Européen Georges-Pompidou, 20, rue Leblanc, Paris, France
b UMR 970 PARCC Inserm, Paris University, Paris, France
c Université de Paris, Innovative Therapies in Hemostasis, Inserm, 75006 Paris, France
d Hematology department and Biosurgical Research lab (Carpentier Foundation), AP–HP, Georges Pompidou European Hospital, 75015 Paris, France
e Emergency department, AP–HP, Paris University, Paris, France
f Oncology department, AP–HP, Paris University, Paris, France

Received 13 June 2021; accepted 21 October 2021
Available online 1 November 2021

KEYWORDS
Hypokalemia; COVID-19; SARS-CoV-2; ICU; Coronavirus; Prognosis

Summary
Background. — SARS-CoV-2 uses Angiotensin-Converting Enzyme 2 as a viral gateway to the cell and could interact with the renin-angiotensin-aldosterone system. Other studies have shown kalemia abnormalities in patients with severe forms of coronavirus disease 2019. Our goal was to assess the prognosis value of kalemia within ten days of symptom offset in the COVID-19 hospitalized population.

Methods. — We analyzed data from a prospective cohort that included 65 patients with COVID-19, admitted between March 15, 2020, and March 21, 2020. The study aimed at determining the relationship between baseline kalemia and the admission to an intensive care unit (ICU) or death.

* Corresponding author.
E-mail address: emmanuel.messas@aphp.fr (A.F. Guédon).

https://doi.org/10.1016/j.jdmv.2021.10.006
2542-4513/© 2021 Elsevier Masson SAS. All rights reserved.
Background

A major coronavirus disease 2019 (COVID-19) outbreak hit Wuhan in December 2019 before rapidly spreading around the world, infecting more than 126 million people [1—3]. The first case in Europe was diagnosed in France on January 24, 2020 [4], followed by a massive outbreak. Studies have shown that the virus was using the Angiotensin-Converting Enzyme 2 (ACE-2) as a viral gateway to penetrate host cells and could have interactions with the renin-angiotensin system (RAS) [5—12]. However, a recent study showed a high prevalence of hypokalemia in COVID patients might be due to RAS dysregulation. Moreover, an association was found between the intensity of the low potassium level and some clinical and biological signs of COVID-19 disease severity [13,14]. Therefore, hypokalemia disorders could be an indirect sign of the clinical severity of the disease, without any knowledge of whether they impact more robust prognostic criteria such as admission to an intensive care unit (ICU) or death. To confirm those findings, we assessed the prognosis value of hypokalemic (lower level within ten days of symptom offset) in the COVID-19 population hospitalized in our institution.

Methods

Study population

In this single-center prospective cohort, 65 patients were consecutively enrolled between March 15, 2020, and March 21, 2020, in Georges Pompidou European Hospital in Paris (France) with SARS-CoV-2 infection as previously described [15]. Patients over 18 years who had criteria for hospitalization according to local guidelines and who received a diagnosis of SARS-CoV-2 infection confirmed by a nasopharyngeal swab test were included. We followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines [16]. The institutional ethical committee approved the study (SARCODO study; CPP2020-04-048/2020-A01048-31/20.04.21.49318), and patients gave standard written consent to the use of their data.

Study design

We classified patients into two groups according to the median baseline hypokalemia—low hypokalemia (≤ 3.8 mmol/L) and no low hypokalemia (> 3.8 mmol/L). A hypokalemia result was considered baseline if recorded within ten days of the first symptom onset. Patients were considered to have a low hypokalemia occurrence if they had at least one baseline hypokalemia less than or equal to 3.8 mmol/L within ten days of the first symptoms onset. This period corresponds approximately to the median time to acute respiratory distress syndrome (ARDS) or ICU admission found in the literature [1,17—19]. We aimed to compare clinical characteristics and laboratory findings between those groups and analyze the prognostic value of baseline hypokalemia.

Data Collection

Baseline characteristics, including demographic, clinical, biological, radiological, and outcome data were extracted from electronic medical records using a standardized data collection. Laboratory findings included serum hypokalemia level, serum creatinine level, hemogram, C-reactive protein (CRP) level, D-dimer level, and troponin level. We used a score based on the percentage of lung involvement assessed by chest computed tomography (CT) as a CT severity score ranging from 0 to 4—0 as normal, 1 as < 25% abnormality, 2 as 25—50% abnormality, 3 as 50—75% abnormality, and 4 as > 75% abnormality [20]. Recorded treatments included beta-blockers, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blockers (ARB-2), diuretics, centrally acting antihypertensive, and non-steroidal anti-inflammatory drugs (NSAIDs).

Outcome

The primary composite outcome was defined as admission to an ICU or in-hospital death. Secondary outcomes included maximum CRP serum level—defined as the highest CRP value recorded during the patient’s stay, the maximum oxygen flow rate—defined as the highest oxygen flow rate administration during the patient’s stay and the minimum hemoglobin level, defined as the lowest hemoglobin level presented by the patients during the hospital stay.

Statistical analysis

Continuous variables were expressed as median (interquartile range [IQR]), and qualitative variables were expressed as number (proportion). The primary outcome evaluation
was done by considering the time calculated from symptom onset, defined as the date on which symptoms first began, to in-hospital death or ICU admission, or the last follow-up contact. We presented kalemia, CRP, and oxygen administration trends as a time plot showing the respective medians according to the time from symptom onset. Creatinine serum level variable has been log-transformed to achieve normality. Serum potassium levels were dichotomized based on the median value to create two groups: patients who had a low kalemia occurrence (<3.8 mmol/L) and those who had no low kalemia occurrence (>3.8 mmol/L). We used a bootstrap method with 10 000 replications to calculate 95% confidence intervals (CIs) for median and proportion differences between both groups [21]. Those CIs have not been adjusted for multiple testing and should not allow inference interpretation. Multiple imputations were used to handle missing data [22]. No variable had more than 5% missing data except for the CT scan severity score, which is shown in baseline characteristics but not included in the analysis. No previous hypothesis was chosen, and no sample size was calculated as this was an exploratory study. Kaplan-Meier and adjusted Cox proportional hazards models were used to evaluate the association between low kalemia and the primary outcome. Proportional-hazards assumptions were tested graphically using scaled Schoenfeld residuals. Adjusted logistic regressions were used to analyze the association between low kalemia occurrence and secondary outcomes. All logistic regression model assumptions were met adequately. No interaction was found between variables. Adjusted variables were chosen a priori according to their potential impact on kalemia or prognosis—serum creatinine level, the presence of an ACE inhibitor or ARB-2, the presence of a diuretic, the maximum oxygen flow rate, age, and the D-dimer levels [23,24]. Final variables included in models assessing primary and secondary outcomes were chosen according to the best model fit based on the lowest Akaike information criterion. We considered a two-sided p-value <0.05 as significant. Tests were only performed on primary and secondary outcomes to limit inflation of the type I error. These explanatory analyses were performed using R software 3.6.0 version for Mac (Foundation for Statistical Computing, Vienna, Austria).

Results

Patient characteristics

Sixty-five patients were included with a median age of 63.00 [IQR: 54.00, 79.00] years, including 43 males (66.2%). The main baseline clinical and demographic characteristics are summarized in Table 1. Concerning cardiovascular risk factors, almost half of the patients had hypertension at baseline (43.8%), one-third of the patients were current or former smoker (current smoker: 6.8%, former smoker: 20.5), approximately one-sixth of the patients were diabetic (16.9%) and one-third of the patients had dyslipidemia (29.2%). The most frequent symptoms were fever (93.8%), cough (73.4%), and dyspnea (46.9%). Very few presented with diarrhea (10.9%). Abnormal laboratory findings were increased CRP level (median: 74.00 mg/L, IQR: 21.55–126.50 mg/L), decreased lymphocytes (median: 0.90 G/L, IQR: 0.69–1.18 G/L), and increased D-dimer levels (median: 999.00 μg/L, IQR: 692.00–1778.00 mg/L). Median [IQR] kalemia values at baseline were 3.90 [3.60–4.20] mmol/L. One-third of patients took an ACE inhibitor or ARB-2 at the inclusion (ACE inhibitor: 15.4%, ARB-2: 13.8), and only four patients received NSAIDs (6.2%). From available scannographic data, most patients had a CT scan severity

| Characteristic                  | Patients (n = 65) |
|---------------------------------|------------------|
| Median age [IQR]—year           | 63.00 [54.00, 79.00] |
| Median weight [IQR]—kilogram    | 75 [65.80, 86.25] |
| Median height [IQR]—meter       | 1.71 [1.65, 1.77] |
| Median Body Mass-Index [IQR]—kg/m² | 25.03 [23.59, 28.00] |
| Male sex—no. (%)                | 43 (66.2) |
| Diabetes—no. (%)                | 11 (16.9) |
| Smoking status—no./total no. (%)| Current smoker 3/44 (6.8) |
|                                | Former smoker 9/44 (20.5) |
|                                | Never smoked 32/44 (72.7) |
| Hypertension—no./total no. (%)  | 28/64 (43.8) |
| Dyslipidemia—no. (%)            | 19 (29.2) |
| Asthenia—no. (%)                | 28 (43.1) |
| Fever—no. (%)                   | 61 (93.8) |
| Headache—no./total no. (%)      | 13/64 (20.3) |
| Dyspnea—no./total no. (%)       | 30/64 (46.9) |
| Cough—no./total no. (%)         | 47/64 (73.4) |
| Diarrhea—no./total no. (%)      | 7/64 (10.9) |
| Median serum creatinine [IQR]—μmol/L | 79.00 [61.50, 106.50] |
| Median CRP [IQR]—mg/L           | 74.00 [21.55, 126.50] |
| Median haemoglobin [IQR]—g/dL   | 13.00 [11.20, 14.40] |
| Median lymphocytes [IQR]—G/L    | 0.90 [0.69, 1.18] |
| Median neutrophils [IQR]—G/L    | 3.95 [2.99, 5.90] |
| Median kalemia [IQR]—mmol/L     | 3.90 [3.60, 4.20] |
| Median D-dimer [IQR]—μg/L       | 999.00 [692.00, 1778.00] |
| Median troponin [IQR]—ng/L      | 8.50 [5.05, 20.55] |
| Beta-blockers—no. (%)           | 8 (12.3) |
| Calcium channel blockers—no. (%)| 11 (16.9) |
| ACE inhibitor or ARB-2—no. (%)  | None 46 (70.8) |
|                                | ACE inhibitor 10 (15.4) |
|                                | ARB-2 9 (13.8) |
| Diuretics—no. (%)               | 6 (9.2) |
| Centrally acting               | 1 (1.5) |
| antihypertensive—no. (%)        | 4 (6.2) |
| NSAIDs—no. (%)                  | 4 (6.2) |
| CT scan severity score—no./total no. (%) | 0 5/39 (12.8) |
|                                | 1 12/39 (30.8) |
|                                | 2 15/39 (38.5) |
|                                | 3 5/39 (12.8) |
|                                | 4 2/39 (5.3) |
Table 2  Clinical characteristics of patients according to the presence of a baseline low kalemia.

| Characteristic                                   | Patients with a kalemia > 3.8 mmol/L (n = 34) | Patients with a kalemia ≤ 3.8 mmol/L (n = 31) | Difference [95% CI] |
|--------------------------------------------------|-----------------------------------------------|-----------------------------------------------|-------------------|
| Median age [IQR]—year                             | 63.50 [52.25, 82.25]                          | 63.00 [55.00, 77.00]                          | 0.50 [−15.00; 17.00] |
| Median weight [IQR]—kilogram                      | 75.00 [69.75, 83.15]                          | 77.00 [64.00, 90.00]                          | −2.00 [−14.80; 7.00] |
| Median height [IQR]—meter                         | 1.72 [1.68, 1.80]                              | 1.70 [1.63, 1.75]                              | 0.02 [−0.04; 0.07]  |
| Median Body Mass-Index [IQR]—kg/m2                | 24.84 [23.85, 27.62]                           | 26.35 [23.46, 28.73]                           | −1.51 [−3.87; 1.17] |
| Male sex—no. (%)                                  | 23 (67.6)                                     | 20 (64.5)                                     | 3.1 [−21.0; 25.2]  |
| Diabetes—no. (%)                                  | 7 (20.6)                                      | 4 (12.9)                                      | 7.7 [−11.1; 25.0]  |
| Smoking status—no./total no. (%)                  |                                              |                                              |                   |
| Current smoker                                    | 1/22 (4.5)                                    | 2/22 (9.1)                                    | −4.6 [21.1; 9.0]   |
| Former smoker                                     | 5/22 (22.7)                                   | 4/22 (18.2)                                   | 4.5 [−19.8; 29.0]  |
| Never smoked                                      | 16/22 (72.7)                                  | 16/22 (72.7)                                  | 0.0 [−26.7; 25.4]  |
| Hypertension—no./total no. (%)                    | 14/33 (42.4)                                  | 14/31 (45.2)                                  | −2.8 [−26.8; 22.0] |
| Dyslipidemia—no. (%)                              | 10 (29.4)                                     | 9 (29.0)                                      | 0.4 [−21.9; 21.8]  |
| Asthenia—no. (%)                                  | 15 (44.1)                                     | 13 (41.9)                                     | 2.2 [−22.5; 26.0]  |
| Fever—no. (%)                                     | 33 (97.1)                                     | 28 (90.3)                                     | 6.8 [−2.9; 19.6]   |
| Headache—no./total no. (%)                        | 6/33 (18.2)                                   | 7/31 (22.6)                                   | −4.4 [−24.2; 14.8] |
| Dyspnea—no./total no. (%)                         | 13/33 (39.4)                                  | 17/31 (54.8)                                  | −15.4 [−38.3; 10.0] |
| Cough—no./total no. (%)                           | 24/33 (72.7)                                  | 23/31 (74.2)                                  | −1.5 [−23.1; 20.0] |
| Diarrhea—no./total no. (%)                        | 3/34 (8.8)                                    | 4/30 (13.3)                                   | −4.5 [−22.6; 8.5]  |
| Median serum creatinine [IQR]—μmol/L              | 83.50 [65.75, 130.50]                          | 71.00 [59.00, 86.00]                          | 12.50 [−9.00; 39.00]|
| Median CRP [IQR]—mg/L                             | 74.50 [20.38, 114.50]                          | 66.80 [34.60, 140.00]                         | 7.70 [−43.00; 46.07]|
| Median haemoglobin [IQR]—g/dL                     | 13.00 [11.22, 14.80]                           | 13.00 [11.10, 14.15]                          | 0.00 [−1.80; 1.70]  |
| Median Lymphocytes [IQR]—G/L                      | 0.94 [0.63, 1.16]                              | 0.87 [0.72, 1.35]                              | 0.07 [−0.20; 0.23]  |
| Median neutrophils [IQR]—G/L                      | 4.26 [3.07, 5.87]                              | 3.89 [2.66, 5.75]                              | 0.37 [−0.83; 1.87]  |
| Median D-dimer [IQR]—μg/L                         | 1292.00 [761.50, 2517.50]                     | 978.00 [683.75, 1525.50]                      | 314.00 [−226.50; 1519.80] |
| Median Troponin [IQR]—ng/L                        | 12.35 [5.30, 20.85]                            | 7.10 [4.95, 18.50]                            | 5.25 [−6.50; 14.90] |
| Beta-blockers—no. (%)                             | 4 (11.8)                                      | 4 (12.9)                                      | −1.1 [−17.3; 14.1] |
| Calcium channel blockers—no. (%)                  | 4 (11.8)                                      | 7 (22.6)                                      | −10.8 [−30.2; 5.0]  |
| ACE inhibitor or ARB-2—no. (%)                    | None                                          | 22 (64.7)                                     | −12.7 [−34.2; 9.0] |
| ACE inhibitor                                     | 7 (20.6)                                      | 3 (9.7)                                       | 10.9 [−7.3; 26.5]  |
| ARB-2                                            | 5 (14.7)                                      | 4 (12.9)                                      | 1.8 [−16.4; 17.4]  |
| Diuretics—no. (%)                                 | 3 (8.8)                                       | 3 (9.7)                                       | −0.9 [−16.4; 11.5] |
| Centrally acting antihypertensive—no. (%)         | 0 (0.0)                                       | 1 (3.2)                                       | −3.2 [−22.6; 0.0]  |
| NSAIDs—no. (%)                                    | 1 (2.9)                                       | 3 (9.7)                                       | −6.8 [−22.6; 2.4]  |
| CT scan severity score—no./total no. (%)         |                                              |                                              |                   |
| 0                                                | 3/17 (17.6)                                   | 2/21 (9.5)                                    | 8.1 [−11.5; 33.3]  |
| 1                                                | 4/17 (23.5)                                   | 7/21 (33.3)                                   | −9.8 [−37.0; 21.2] |
| 2                                                | 8/17 (47.1)                                   | 7/21 (33.3)                                   | 13.7 [−18.7; 44.6] |
| 3                                                | 2/17 (11.8)                                   | 3/21 (14.3)                                   | −2.5 [−22.2; 21.1] |
| 4                                                | 0/17 (0.0)                                    | 2/21 (9.5)                                    | −9.5 [−31.3; 0.0]  |

a The 95% confidence intervals (CIs) of the differences have not been adjusted for multiple testing and should not allow inference interpretation

score of 1 (30.8%) or 2 (38.5%), and only 5.3% of patients had a score of 4.

Outcome results

The baseline characteristics of those groups were well balanced according to the 95% confidence interval differences available in Table 2.

Patients were split according to the median kalemia level (3.9 mmol/L) into two groups—low kalemia occurrence (≤ 3.8 mmol/L) and no low kalemia occurrence (> 3.8 mmol/L).

Fig. 1 shows trends in median kalemia, CRP levels, and oxygen administration since the first day of symptoms. In Table 3, the unadjusted analysis did not find any significant difference between both groups concerning the median difference of the highest oxygen flow rate administration, the highest CRP level, or the lowest hemoglobin level presented by patients during the hospital stay. Fig. 2 shows the Kaplan–Meier curves for the primary outcome (admission to an ICU or death) during the hospital stay. Twelve patients
(38.7%) were admitted to an intensive care unit or died in the low kalemia group against nine patients (26.5) in the other group (adjusted hazard ratio, 3.52; 95% CI, 1.12 to 11.04; \( P = 0.0309 \)). No association was found between patients with a baseline kalemia ≤ 3.8 mmol/L and maximum oxygen flow rate required by the patients (odds ratio, 1.05; 95% CI, 0.90 to 1.23), or between baseline kalemia and the maximum CRP value (odds ratio, 1.00; 95% CI, 1.00 to 1.01). However, a significant adjusted association was found between baseline kalemia and the minimum hemoglobin level presented by the patients during the hospital stay (odds ratio, 0.80; 95% CI, 0.64 to 0.99).

### Discussion

This prospective monocentric observational study investigates the prognosis value of kalemia in hospitalized COVID-19 patients and its association with laboratory findings. The results suggest that low levels of kalemia within ten days of the first symptom onset are associated with admission in ICU or death and with the minimum hemoglobin level presented by the patients during the hospital stay. However, we did not find any association between kalemia and CRP levels or the oxygen administration, but our study might be underpowered to detect any of them.
A recent study showed that patients with COVID-19 had a higher incidence of hypokalemia and that the intensity of hypokalemia was associated with disease severity in terms of clinical symptoms and biomarkers [13]. To our knowledge, our study is the only one that showed a prognostic impact of kalemia on ICU admission or death.

However, these findings have some limitations. The frequency of kalemia sampling depended on the clinician’s appreciation and the patient’s need for monitoring. Besides, we do not know any kalemia value before hospitalization since blood samples were performed at the hospital or any potential potassium supplementation from medical records. Thus, the potassium measurement is not optimal, and it could be interesting to perform a new study with regular and standardized potassium monitoring. Otherwise, a significant amount of missing data prevented us from analyzing the CT-scan severity scores. It would have been interesting to explore the relationship between kalemia and scannographic severity. Our study is exploratory and cannot give rise to inference interpretations since it only concerns one center and patients who required hospitalization. A significant limitation is the lack of data on kaliuresis, which could have informed us of the origin of the potassium loss. However, a recent study [13] showed an increased urinary K+ output in patients with hypokalemia compared with patients with normokalemia and suggested it is caused by a dysfunction of the renin-angiotensin system (RAS). Indeed, SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE-2), a metalloproteinase involved in the renin-angiotensin system [6], to gain entry into the host cell [8,9]. The binding between ACE-2 and the SARS-CoV2 Spike protein downregulates ACE-2 [10], which mechanically increases the concentrations of angiotensin I and angiotensin II [11,12] and explains the urinary loss of potassium due to a secondary increase of aldosterone [5]. Moreover, some authors suggest that reduced ACE-2 activity could be associated with poor prognosis in patients with acute respiratory distress syndrome [25]. In our study, a low kalemia value could be an early sign of a more significant ACE-2 reduction, and therefore a sign of vulnerability to the infection. Kalemia could constitute another critical element to assess for the COVID-19 prognostic along with D-dimer, troponin levels [26,27], or markers of endothelial activation [28,29], and it might be interesting to investigate the clinical relevance of a gravity score combining them.

**Conclusion**

Our study shows that low levels of kalemia within ten days of the first symptom onset is a prognostic factor for ICU admission or death in COVID-19 hospitalized patients. Further studies should be conducted on a larger scale to confirm our results to understand better the pathophysiological links between RAS, kalemia disorders, and prognosis in patients with COVID-19.
Funding
This work has been funded with grants from the French national agency for research and Fondation de France (ANR SARCODO).

Disclosure of interest
The authors declare that they have no competing interest.

Acknowledgments
We would like to acknowledge all nurses, technicians, and physicians involved in the Vascular medicine, Internal medicine, Respiratory medicine, Intensive care, Clinical investigation center and Hematology departments of the George Pompidou European Hospital and Cochin Hospital for their help in taking care of patients and including them in the study. We thank AP-HP for the promotion of the SARCODO Project. We thank the unit of clinical research URC HEGP CIC-EC1418 (Natacha Nohile, Pauline Jouany, and Dr. Juliette Djadi-Prat) and Helene Cart-Grandjean from AP-HP for their involvement in the SARCODO project.

Online Supplement. Supplementary data
Supplementary data associated with this article can be found in the online version, at https://doi.org/10.1016/j.jdmv.2021.10.006.

References
[1] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus–infected pneumonia in Wuhan, China. JAMA 2020;323:1061–9. http://dx.doi.org/10.1001/jama.2020.1585.
[2] World Health Organization. Coronavirus disease (COVID-19) Weekly Epidemiological Update 2021. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19–31-march-2021.(accessed April 2, 2021).
[3] Debuc B, Smadja DM. Is COVID-19 a new hematologic disease? Stem Cell Rev and Rep 2021;17:4–8. http://dx.doi.org/10.1007/s12015-020-09987-4.
[4] Stoecklin SB, Rolland P, Silue Y, Mailles A, Campese C, Simondon A, et al. First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020. Euro Surveill 2020;25:2000094. http://dx.doi.org/10.2807/1560-7917.ES.2020.25.6.2000094.
[5] Silhol F, Sarlon G, Deharo J-C, Vaisse B. Down-regulation of ACE2 induces overstimulation of the renin–angiotensin system in COVID-19: should we block the renin–angiotensin system? Hypertens Res 2020;43:854–6. http://dx.doi.org/10.1080/01440204.2020.1790849.
[6] Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Saglione N, et al. A novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) converts Angiotensin I to Angiotensin 1-9. Circ Res 2000;87:e1–9. http://dx.doi.org/10.1161/01.RES.87.5.e1.
[7] Hamming I, Timens W, Bulthuis M, Lely A, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004;203:631–7. http://dx.doi.org/10.1002/path.1570.
[8] Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origin and receptor binding. Lancet 2020;395:565–74. http://dx.doi.org/10.1016/S0140-6736(20)30251-8.
[9] Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS Coronavirus. J Virol 2020;94:e00127–220. http://dx.doi.org/10.1128/JVI.00127-20.
[10] Imai Y, Kuba K, Penninger JM. The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. Exp Physiol 2008;93:543–8. http://dx.doi.org/10.1113/expphysiol.2007.040048.
[11] Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counterregulatory Actions of Angiotensin-(1-7). Hypertension 1997;30:535–41. http://dx.doi.org/10.1161/01.HYP.30.3.535.
[12] Battle D, Wysocki J, Sofer MJ, Ranganath K. Angiotensin-converting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy. Kidney Int 2012;81:520–8. http://dx.doi.org/10.1038/ki.2011.381.
[13] Chen D, Li X, Song Q, Hu C, Su F, Dai J, et al. Assessment of hypokalemia and clinical characteristics in patients with Coronavirus Disease 2019 in Wenzhou, China. JAMA Netw Open 2020;3:e2011122. http://dx.doi.org/10.1001/jamanetworkopen.2020.11122.
[14] Moreno PO, Leon-Ramirez J-M, Fuertes-Kenneally L, Perdiiguro M, Andres M, Garcia-Narvallo M, et al. Hypokalemia as a sensitive biomarker of disease severity and the requirement for invasive mechanical ventilation requirement in COVID-19 pneumonia: a case series of 306 Mediterranean patients. Int J Infect Dis 2020;100:449–54. http://dx.doi.org/10.1016/j.ijid.2020.09.033.
[15] Khider L, Gendron N, Goudot G, Chen X, Hauw-Berlemont C, Cheng C, et al. Curative anticoagulation prevents endothelial lesion in COVID-19 patients. J Thromb Haemost 2020;18:2391–9. http://dx.doi.org/10.1111/jth.14968.
[16] Elm von E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenburgroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453–7. http://dx.doi.org/10.1016/S0140-6736(07)61602-X.
[17] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506. http://dx.doi.org/10.1016/S0140-6736(20)30183-5.
[18] Zhou F, Yu T, Du R, Fan G, Liu Y, Li Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62. http://dx.doi.org/10.1016/S0140-6736(20)30566-3.
[19] Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;8:475–81. http://dx.doi.org/10.1016/S2213-2600(20)30079-5.
[20] Yuan M, Yin W, Tao Z, Tan W, Hu Y. Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China. PLoS One 2020;15:e0230548. http://dx.doi.org/10.1371/journal.pone.0230548.
[21] Efron B, Tibshirani R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Statist Sci 1986;1:54–75. http://dx.doi.org/10.1214/ss/1177013815.
[22] White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med 2011;30:377–99, http://dx.doi.org/10.1002/sim.4067.

[23] Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost 2020;18:1324–9, http://dx.doi.org/10.1111/jth.14859.

[24] Sakka M, Connors JM, Hékimian G, Martin-Toutain I, Crichi B, Colmegna I, et al. Association between D-Dimer levels and mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and pooled analysis. J Med Vasc 2020;45:268–74, http://dx.doi.org/10.1016/j.jdmv.2020.05.003.

[25] Reddy R, Asante I, Liu S, Parikh P, Liebler J, Borok Z, et al. Circulating angiotensin peptides levels in Acute Respiratory Distress Syndrome correlate with clinical outcomes: a pilot study. PLoS One 2019;14:e0213096, http://dx.doi.org/10.1371/journal.pone.0213096.

[26] Goudot G, Chocron R, Augy J-L, Gendron N, Khider L, Debuc B, et al. Predictive factor for COVID-19 worsening: insights for high-sensitivity Troponin and D-Dimer and correlation with right ventricular afterload. Front Med 2020;7, http://dx.doi.org/10.3389/fmed.2020.586307.

[27] Chocron R, Duceau B, Gendron N, Ezzouhairi N, Khider L, Trimalle A, et al. D-dimer at hospital admission for COVID-19 are associated with in-hospital mortality, independent of venous thromboembolism: Insights from a French multicenter cohort study. Arch Cardiovasc Dis 2021;114:381–93, http://dx.doi.org/10.1016/j.acvd.2021.02.003.

[28] Philippe A, Chocron R, Gendron N, Bory O, Beauvais A, Peron N, et al. Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. Angiogenesis 2021;24:505–17, http://dx.doi.org/10.1007/s10456-020-09762-6.

[29] Smadja DM, Guerin CL, Chocron R, Yatim N, Boussier J, Gendron N, et al. Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients. Angiogenesis 2020;23:611–20, http://dx.doi.org/10.1007/s10456-020-09730-0.